TICKERNERD
Menu
ABTABTHealthcare · Medical Devices

ABT Stock Forecast: Abbott Laboratories Price Predictions for 2026-2027

Last close, 14 Aug 2026
$111
−0.02% on the day

The 27 Wall Street analysts covering Abbott Laboratories hold a median 12-month price target of $119 — +6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 13 Aug 2026 — in the upper half.

Market cap
$191.9B
Ticker Nerd rank
53 / 100
Median analyst target
$119
Analysts covering
27
Total return, dividends reinvested
1W
+3.2%
1M
+25.9%
YTD
−9.6%
1Y
−12.0%
From 52W high
−16.7%
From 52W low
+35.7%
$82
$134
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Abbott Laboratories on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Quality
84
Value
81
Revisions
79
Growth
48
Accruals
39
Issuance
37
Momentum
17
Size
1

Volatility (99): The share price has been relatively steady.

Momentum (17): The shares have been drifting down relative to others.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$90$100$110$120$130$140Oct 25Jan 26Apr 26Jul 26ABTHigh $135Median $119Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
20 Buy7 Hold0 Sell
Low $103Median $119High $135

The green dot is the last close — the median target sits +6.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
28 July 2026UBSMaintainsBuy$135 → $125
17 July 2026BTIGMaintainsBuy$131 → $134
17 July 2026BTIGMaintainsBuy—
17 July 2026CitigroupMaintainsBuy—
17 July 2026CitigroupMaintainsBuy$108 → $112
17 July 2026Evercore ISI GroupMaintainsOutperform—
17 July 2026Evercore ISI GroupMaintainsOutperform$112 → $120
17 July 2026JP MorganMaintainsOverweight$110 → $120
17 July 2026JP MorganMaintainsOverweight—
17 July 2026Piper SandlerReiteratesOverweight—
17 July 2026Piper SandlerReiteratesOverweight$115 → $118
17 July 2026RBC CapitalReiteratesOutperform$130
17 July 2026RBC CapitalReiteratesOutperform—
17 July 2026TD CowenReiteratesBuy—
17 July 2026TD CowenReiteratesBuy$115
17 July 2026Wells FargoMaintainsOverweight—
17 July 2026Wells FargoMaintainsOverweight$109 → $112
6 July 2026Evercore ISI GroupMaintainsOutperform—
1 July 2026BairdInitiatesOutperform—
22 June 2026Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ABT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
19
Analysts cutting
2
Fundamentals

Abbott Laboratories (ABT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.9×

Cheaper than 23% of US stocks

Price / sales
4.1×

Cheaper than 31% of US stocks

Price / book
3.8×

Cheaper than 29% of US stocks

EV / EBITDA
18.6×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
13.0%

Higher than 60% of US stocks

Earnings growth (YoY)
−47.8%

Higher than 11% of US stocks

Gross margin
56.2%

Higher than 69% of US stocks

Operating margin
14.7%

Higher than 72% of US stocks

Net margin
11.6%

Higher than 73% of US stocks

Returns & dividend
Return on equity
10.6%

Higher than 65% of US stocks

Return on assets
5.3%

Higher than 78% of US stocks

Dividend yield
2.3%

Higher than 51% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ABT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ABTAbbott Laboratories$191.9B
53
SYKStryker Corp.$130.4B
74
MDTMedtronic PLC$116.1B
83
BSXBoston Scientific Corp.$76.6B
57
EWEdwards Lifesciences Corp.$53.3B
91
DXCMDexCom, Inc.$35.3B
98
GEHCGE Healthcare Technologies, Inc.$33.6B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Abbott Laboratories — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABT news & analysis

What's Backing Abbott's Established Pharmaceuticals Division Growth

Zacks Investment Research · 13 Aug 2026positive

Abbott Laboratories' Established Pharmaceuticals Division growth is being supported by strong emerging-market demand, a broad portfolio of branded generics, and rising healthcare demand, with biosimilars adding further opportunities, according to Zacks Investment Research.

Why it matters — For Abbott watchers, the EPD segment's growth drivers point to a durable source of revenue expansion across emerging markets and the generics/biosimilars space.

Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis

PRNewsWire · 12 Aug 2026positive

Abbott and the Big Ten are relaunching the "We Give Blood" competition, which brings together all 18 Big Ten schools in a drive to generate blood donations, with Abbott offering $1 million to the school with the most donations. The initiative comes as the American Red Cross declared a national blood crisis for only the second time in its history, after summer donations fell to a four-year low; donations between Aug. 12 and Dec. 4 can be logged toward schools starting Aug. 26.

Why it matters — The campaign highlights Abbott's community-engagement and public-health initiatives, reinforcing its brand and social responsibility at a time of a declared national blood shortage.

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

PRNewsWire · 11 Aug 2026positive

Abbott announced a multi-year partnership with Google Health to integrate data from its Lingo continuous glucose monitor with Google's technology and AI coaching. The collaboration also includes a large-scale research study to inform future product features.

Why it matters — The partnership signals Abbott's expansion beyond medical devices into consumer digital health and AI, potentially broadening the reach and appeal of its Lingo biowearable.

Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research published a piece on Abbott Laboratories (ABT) stock amid a medical devices boom. It notes that Abbott's Medical Devices growth, Established Pharmaceuticals Division momentum, and improving Nutrition segment support its outlook, while China risks, costs, and valuation warrant caution.

Why it matters — ABT watchers would care because the item weighs the company's key growth drivers against the risks that could influence its near-term prospects.

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 7 Aug 2026neutral

The Motley Fool published a comparison of AbbVie and Abbott Laboratories as potential healthcare stock picks for 2026. The article notes that AbbVie relies on a high-margin biopharmaceutical portfolio and free cash flow, while Abbott leverages a diversified business spanning medical devices, diagnostics, and nutritional products.

Why it matters — The article highlights Abbott's diversified business model as a key point of comparison for investors tracking the company.

FAQ

Frequently asked questions about ABT stock

What is the ABT stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Abbott Laboratories have a median 12-month price target of $119, with estimates ranging from $103 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABT stock a buy right now?

Of the 27 analysts covering Abbott Laboratories, 20 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abbott Laboratories 53 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABT?

As at 13 Aug 2026, Abbott Laboratories ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will ABT stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +6.5% from the last close, and Ticker Nerd's factor model ranks Abbott Laboratories 53 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABT stock forecast for 2030?

No analyst covering Abbott Laboratories publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $135 over the next 12 months.

How has ABT stock performed over the past year?

Abbott Laboratories returned -12.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Abbott Laboratories do?

Abbott Laboratories is a global healthcare company that develops and markets a broad portfolio of medical devices, diagnostics, nutritional products, and branded generic medicines. Its current business is organized around four core segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products.

What is the latest news on ABT?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "What's Backing Abbott's Established Pharmaceuticals Division Growth". Abbott Laboratories' Established Pharmaceuticals Division growth is being supported by strong emerging-market demand, a broad portfolio of branded generics, and rising healthcare demand, with biosimilars adding further opportunities, according to Zacks Investment Research.

Company

About Abbott Laboratories.

Abbott Laboratories is a global healthcare company that develops and markets a broad portfolio of medical devices, diagnostics, nutritional products, and branded generic medicines. Its current business is organized around four core segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Abbott’s medical device portfolio includes technologies used in areas such as cardiovascular care, diabetes management, neuromodulation, and structural heart treatment, while its diagnostics business supplies testing systems and rapid assays used by hospitals, laboratories, and other care settings. The company’s nutrition products serve infants, children, and adults through clinically oriented formulas and everyday nutrition brands. Abbott Laboratories also sells branded generic medicines in international markets, supporting access to established therapies across multiple regions. Headquartered in Abbott Park, Illinois, Abbott plays a significant role in global healthcare by serving consumers, healthcare providers, and institutions across a wide range of clinical and everyday health needs.

CEO Mr. Robert B. Ford · 122,000 employees · United States · https://www.abbott.com